Table 1 Basic characteristics of the studies included in the analysis
Study | Study Design | Country | Interventions and doses (mg) | Number of patients |
|---|---|---|---|---|
Anagha 2018 [21] | Prospective study | Australia, Switzerland | IVA: 2.0 /IVR: 0.5 | 50/42 |
Sarraf 2016 [22] | Post-hoc analysis of RCT | U.S | IVR: 2.0 /IVR: 0.5 | 298/300 |
Chan 2015 [23] | RCT | U.S | IVR: 2.0 /IVR: 0.5 | 23/13 |
Au 2016 [24] | Retrospective study | U.S | IVA: 2.0 /IVR: 0.5 | 30/23 |
Park 2016 [25] | Retrospective study | South Korea | IVA: 2.0 /IVR: 0.5 | 74/87 |
Rouvas 2018 [26] | Retrospective study | Greece | IVA: 2.0 /IVR: 0.5 | 33/38 |
Ulusoy 2021 [27] | Retrospective study | Turkey | IVA: 2.0 /IVR: 0.5 | 25/33 |